Stockpolly
Search
Delisting risk
MREO · NASDAQ · Biotechnology

Mereo BioPharma Group (ADR) (MREO)

Advances acquired rare-disease drug candidates through clinical development and partnerships.

$0.2651
Pre-market−0.00 (−0.75%)
At close$0.2671(−3.47%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue110000010000
Cost of revenue000000000100
Gross profit010000000−100
78100915111110887
Research & development354039454452
346066756445
General & administrative346060756045
Other expenses000000000000
Operating income−6−7−100−9−15−11−10−10−8−9−7
−2−310−68−2−43120
Interest income111011111000
Interest expense100000000000
Other non-operating income12−1050240000
Income before tax−6−10−90−15−8−13−15−7−8−7−7
Income tax expense0−1000−1000000
Net income from continuing operations−8−9−90−15−7−13−15−7−7−7−7
Other adjustments100000000000
Net income−7−9−90−15−7−13−15−7−7−7−7
EPS, basic−$289.06−$278.56−$0.05$0.00−$0.10−$0.05−$0.09−$0.09−$0.04−$0.05−$0.04−$0.05
EPS, diluted−$289.06−$278.56−$0.05—−$0.50−$0.22−$0.50−$0.09−$0.04−$0.23−$0.04−$0.05
Weighted average shares, basic138138140150150150150160160160160161
Weighted average shares, diluted138138140031313116016032160161
EBITDA−7−9−90−14−15−12−14−10−8−8−7
Depreciation & amortization000000000100
EBIT−8−9−90−15−15−13−15−10−8−9−7